Taiwan:6466.TW

PharmaEssentia Updates Progress of Ropeginterferon Alfa-2b Clinical Program

WALTHAM, Mass., Dec. 5, 2018 /PRNewswire/ -- * 36 month analysis of ropeginterferon alfa-2b (Ropeg) phase III clinical data in Polycythemia Vera (PV) demonstrates superiority across three key aspects of disease control, including complete hematological response (CHR), disease burden, and molec...

2018-12-05 19:00 3005